Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter

Endocrine Journal

Volumn 46, Issue 1, 1999, Pages 221-226

  Güllü, Sevim ^a,b   Gürses, M Ali ^a   Başkal, Nilgün ^a   Uysal, A Riza ^a   Kamel, A Nuri ^a   Erdoǧan, Gürbüz ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Ibni Sina Hastanesi   (Turkey)

Author keywords

Euthyroid goiter; Goiter; Levothyroxine; Nodular goiter; Treatment

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; THYROGLOBULIN; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; LIOTHYRONINE BLOOD LEVEL; MALE; NODULAR GOITER; THYROID WEIGHT; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 16744364525     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.46.221     Document Type: Article

References (26)

1. Celani MF, Mariani M, Mariani G (1980) On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary solid or predominantly solid thyroid nodules. Acta Endocrinol (Copenh) 123: 603-608.
2. Celani MF (1993) Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. Exp Clin Endocrinol 101: 326-332.
3. Diacinti D, Salabe GB, Olivieri A, D'Erasmo E, Tomei E, Lotz-Salabe H, De Martinis C (1992) Efficacy of L-Thyroxine (LT4) therapy on the volume of the thyroid gland and nodules in patients with euthyroid nodular goiter. Minerva Medica 83: 745-751 (In Italian).
4. Koloǧlu S, Başkal N, Toktaş R, Uysal AR, Laleli Y, Koloǧlu LB (1989) Selim nodÜler guvatrin L-tiroksin (LT4) ile supresyon tedavisinin ultrasonografik takip ile deǧerlendirilmesi. Turkiye Klinikleri 9: 464-477 (In Turkish).
5. Morita T, Tamai H, Oshima A, Komaki G, Matsubayashi S, Kuma K, Nakagawa T (1989) Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. J. Clin Endocrinol Metab 69: 227.
6. Milazzo G, La Rosa GL, Catalfamo R, Vigneri R, Belfiore A (1992) Effects of TSH in human thyroid cells: Evidence for both mitogenic and antimitogenic effects. J Cell Biochem 49: 231-238.
7. DeLange F (1994) The disorders induced by iodine deficiency. Thyroid 4: 107-128.
8. Galli C, Calasso F, Cantu G, Carini L, Rumi P, Segalini G (letter)(1987) N Engl J Med 4: 1664.
9. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, German CA (1987) Suppressive therapy with levothyroxine for solitary thyroid nodules: A double blind controlled clinical study. N Engl J Med 317: 70-75.
10. Reverter JL, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A (1992) Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol 36: 25-28.
11. Feldt-Rasmussen U, Hegedus L, Hansen JM, Perrild H (1984) Relationship between thyroid volume and serum thyroglobulin during long term suppression with triiodothyronine in patients with diffuse non-toxic goitre. Acta Endocrinol (Copenh) 105: 184-189.
12. Pezzino V, Vigneri R, Squatrito S, Filetti S, Camus M, Polosa P (1978) Increased serum thyroglobulin levels in patients with non-toxic goitre. J Clin Endocrinol Metab 46: 653-657.
13. Hansen JM, Kaupmann J, Madsen SN, Shovsted L, Solgaard S, Grytter C, Grontvedt T, Rasmussen SN (1979) L-Thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic determination of thyroid volume. Clin Endocrinol (Oxf) 10: 1-6.
14. Hintze G, Emrich D, Köbberling J (1985) Therapy of endemic goitre: Controlled study on the effect of iodine and thyroxine. Horm Metab Res 17: 362-365.
15. Hintze G, Emrich D, Köbberling J (1989) Treatment of endemic goitre due to iodine deficiency with iodine, levothyroxine or both; results of a multicenter trial. Eur J Clin Invest 19: 527-534.
16. Clark OH (1987) TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 5: 39.
17. Cooper DS (1995) Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab 80: 331-334.
18. Papini E, Bacci V, Panunzi C, Pacella CM, Fabbrini R, Bizzarri G, Petrucci L, Giammarco V, La Medica P, Masala M, Pitaro M, Nardi F (1993) A Prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol 38: 507-513.
19. Shimaoko K, Sokal JE (1974) Suppressive therapy of non-toxic goiter. Am J Med 57: 576-583.
20. Rojeski MT, Gharib H (1985) Nodular thyroid disease; Evaluation and management. N Engl J Med 313: 428-435.
21. Berghout A, Wiersinga WM, Drexhage H, Smits NJ, Touber JC (1990) Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 336: 193-197.
22. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM (1998) Long-term changes in nodular goiter: A 5 year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 83: 780-783.
23. Lima N, Knobel M, Cavaliere H, Sztenjnsznajd C, Tomimori E, Medeiros-Neto G (1997) Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 7: 691-697.
24. Perrild H, Hansen JM, Hegedus L, Rytter L, Holm B, Gundtofte E, Johansen K (1982) Triiodothyronin and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh) 100: 382-387.
25. Bongers H, Hotze LA, Schmitz R, Joseph H (1982) LT4 monopreparation versus LT4-LT3 compound preparation in the treatment of diffuse endemic goitre. Acta Endocrinol (Copenh) 113: 242-246.
26. Biersack HJ, Hotze A (1991) The clinician and the thyroid. Eur J Nuc Med 18: 761.